{
    "eid": "2-s2.0-85085047562",
    "title": "Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic\u2013Pharmacogenetic Model of HIV-infected Patients in Thailand",
    "cover-date": "2020-07-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "CYP2B6 516G>T",
        "Dose optimization",
        "Efavirenz",
        "HIV",
        "Population pharmacokinetics\u2013pharmacogenetics",
        "Thailand"
    ],
    "authors": [
        "Piyawat Chaivichacharn",
        "Anchalee Avihingsanon",
        "Weerawat Manosuthi",
        "Sasiwimol Ubolyam",
        "Siraprapa Tongkobpetch",
        "Vorasuk Shotelersuk",
        "Baralee Punyawudho"
    ],
    "citedby-count": 5,
    "ref-count": 43,
    "ref-list": [
        "Thailand ministry of public Health",
        "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients",
        "Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals",
        "Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection",
        "Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS clinical trial group study 398",
        "Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals",
        "High prevalence of the CYP2B6 516G-->T(\u22176) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe",
        "A novel polymorphism in ABCB1 gene, CYP2B6\u22176 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans",
        "Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals",
        "Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients",
        "Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations",
        "CYP2B6\u22176, CYP2B6\u221718, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe",
        "Dose optimization of efavirenz based on individual CYP2B6 polymorphisms in Chinese patients positive for HIV",
        "Population pharmacokinetic modeling to estimate the contributions of genetic and nongenetic factors to efavirenz disposition",
        "Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults",
        "Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults",
        "Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients",
        "High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections",
        "Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients",
        "Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms: a substudy of the ANRS ALIZE trial",
        "Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race",
        "Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-naive HIV-infected patients at 96 weeks: results of the ENCORE1 study",
        "Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study",
        "Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial",
        "Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study",
        "Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 \u22176 and \u221726",
        "Successful efavirenz dose reduction guided by therapeutic drug monitoring",
        "de la Paz Valverde Merino M, Dominguez-Gil Hurle A, Cordero Sanchez M. Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV",
        "Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism",
        "Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver",
        "Model appropriateness and population pharmacokinetic modeling",
        "Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models",
        "Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naive and experienced HIV-1-infected Thai adults",
        "Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese",
        "Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese",
        "Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population",
        "Effect of CYP2B6 gene polymorphisms on efavirenz plasma concentrations in Chinese patients with HIV infection",
        "Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese",
        "Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin",
        "Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients",
        "Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis",
        "CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients",
        "Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nontaburi",
            "@id": "60015728",
            "affilname": "Thailand Ministry of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015728",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Bamrasnaradura Infectious Diseases Institute",
        "Chulalongkorn Academic Advancement",
        "Thai Red Cross AIDS Research Centre"
    ]
}